Drug Database
VE

verapamil (verapamil, Mylan / verapamil SR, Mylan / verapamil ER)

✓ Approved

Mylan · CACNA1C · Small Molecule

What is verapamil?

verapamil is a small molecule developed by Mylan. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand Namesverapamil, Mylan, verapamil SR, Mylan, verapamil ER
CompanyMylan
Drug ClassSmall Molecule
Molecular TargetCACNA1C
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Mylan

Mechanism of Action

Molecular Targets

verapamil acts on 1 molecular target:

CACNA1Ccalcium voltage-gated channel subunit alpha1 C (CACNL1A1, CACNA1C-IT2)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

verapamil is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Vascular disordersHypertension✓ Approved

Related Research Articles

PubMedNatural product research2026-05-24

Chemical components from Uncaria gambir (W.Hunter) Roxb. and their preliminary bioactivities in CDC25B phosphatase inhibition and vasodilatory activity.

Liu Wenyan W, Jin Song S, Wang Ziming Z, Li Xinyue X et al.

The endangered Uncaria gambir (W.Hunter) Roxb. (U. gambir) remains largely unexplored in chemical constituents and bioactivities. Therefore, fifteen compounds (1-15), comprising monoterpene indole alkaloids, lignans, flavonoids, triterpenoids, coumarins, and fatty acids, were isolated from this species. Their inhibitory effects against cell division cycle 25B (CDC25B) phosphatase and vasodilatory activities were then evaluated. Results showed that compound 1 (strictosamide) exhibited a notable inhibitory effect on CDC25B phosphatase, with the IC50 value of 5.4 μM, comparable to the positive control (Na3VO4). Compound 3 (3α-dihydrocadambine) effectively revealed strong vasodilatory activity with EC50 values of 2.4 μM and 2.1 μM, respectively, similar levels comparable to the positive control (verapamil). Interestingly, these activities of compounds 1 and 3 were evaluated for the first time in this work. Moreover, network pharmacology and molecular docking predicted compound 1 to correlate with the p53-Hippo-TGF-β antitumor signalling pathway and compound 3 with the cAMP/cGMP-PKG cardiovascular signalling pathway. This work provides preliminary experimental data for the development of potential lead compounds from U. gambir.

PMID 42176307
Read full article →
PubMedJACC. Case reports2026-05-22

Idiopathic Left Ventricular Tachycardia in an 11-Year-Old Boy.

DeLong Adam A, Flaherty Michael M, Balaguru Duraisamy D

Electrocardiogram demonstrating idiopathic fascicular left ventricular tachycardia. An 11-year-old boy with a history of tuberous sclerosis-related intractable epilepsy exhibited an idiopathic ventricular tachycardia that was resistant to multiple antiarrhythmic treatments, but was responsive to verapamil. We discuss the recognition and treatment of verapamil-sensitive fascicular left ventricular tachycardia. Idiopathic fascicular left ventricular tachycardia in pediatric patients is an uncommon but recognizable arrhythmia. Its management differs from that of more commonly occurring pediatric wide-complex arrhythmias in that it readily responds to verapamil.

PMID 42171581
Read full article →
PubMedAnalytical methods : advancing methods and applications2026-05-22

An advanced GC method for comprehensive residual solvent analysis: overcoming co-elution with orthogonal columns and quantification by mass spectrometry.

Arulraj Ruba R, Vishwanath Vinay V, Duche Sharad S, Mathur Arvind A et al.

A robust and comprehensive gas chromatographic method was developed to identify and quantify the 57 residual solvents listed in the ICH guidelines, all in a single, 30-minute chromatogram. The proposed approach, featuring dual orthogonal column chemistry and a mass spectrometry (MS) detector, significantly improved the resolution and enabled the quantification of low-response and co-eluting solvents such as benzene, chloroform, formamide, pyridine, and 1,2-dichloroethene in a complex matrix of 57 solvents. The VF-624 and HP-5 dual-column was configured in series with an MS detector. Method parameters, such as carrier gas flow rate, oven temperature program, and selection of optimal mass spectrometry acquisition parameters, scan and selected ion monitoring (SIM), were tuned to achieve uncompromised sensitivity, resolution, and reproducibility. The method was validated according to ICH Q2(R1) guidelines and demonstrated acceptable specificity, linearity (R2 > 0.99), accuracy, precision, LOD, and LOQ. The real sample applicability was confirmed through analysis of a spiked fenoterol hydrobromide sample, establishing the method's robustness and suitability for testing the 57 residual solvents in pharmaceutical matrices. Additional evaluation with verapamil hydrochloride, amitriptyline hydrochloride, and their commercial formulations (tablets) further validated its broad applicability.

PMID 42171149
Read full article →
PubMedHealth science reports2026-05-18

The Potential Role of Verapamil Against Fluconazole-Induced Torsade de Pointes: A Critical Review.

Abdel-Razik Noha E NE, Al-Kuraishy Hayder M HM, Al-Gareeb Ali I AI, Soliman Maryam Magdy MM et al.

Fluconazole (FZL) is a broad-spectrum antifungal drug associated with certain serious adverse effects such as polymorphic ventricular arrhythmia due to QT prolongation. Torsade de Pointes (TdP) is a unique type of polymorphic ventricular arrhythmia due to QT prolongation. It has been shown that the calcium-channel blocker verapamil is effective in the management of TdP. Therefore, the present critical review aims to discuss and explain the possible role of verapamil in the prevention of FZL-induced TdP. Databases of Scopus, Cochran, Embase, PubMed, and CENTRAL were examined to recognize suitable publications. Screened articles were designated rendering to exact eligibility criteria including original articles such as prospective and retrospective studies recognizing the role verapamil in the prevention of FZL-induced TdP. The use of FZL is linked with the development of TdP and prolongation of QT, and verapamil use could be effective in the management of TdP. In addition, verapamil has antifungal effects, affects the pharmacokinetics and pharmacodynamics of FZL. Verapamil inhibits the propagation of TdP by inhibiting the deregulation of repolarization early after depolarization in the heart. This critical review suggests that combination of verapamil with FZL leads to more beneficial effects by increasing the antifungal activity of FZL with a significant reduction the development of TdP which is a serious adverse effect of FZL.

PMID 42146719
Read full article →
PubMedJACC. Case reports2026-05-14

Refractory Malignant Arrhythmia in a 4-Year-Old Child With Short QT Syndrome: Persistence for Hope.

Wang Yefeng Y, Zuo Chao C, Zeng Min M, Xiao Yunbin Y et al.

Short QT syndrome (SQTS) is a rare cardiac channelopathy and can cause malignant arrhythmia and sudden cardiac arrest. A 4-year-and-6-month-old girl presented with intermittent convulsions and recurrent ventricular fibrillation requiring multiple electrical cardioversions. Electrocardiogram revealed a QTc interval ranging from 294 to 324 milliseconds and polymorphic ventricular tachycardia. Whole-exome sequencing was performed, which revealed no mutations in ion channel-related genes. Quinidine can prolong the QT interval but failed to reduce the occurrence of premature ventricular arrhythmia. Based on the origin site of premature ventricular contractions and literature reports, verapamil and mexiletine were added to the treatment regimen. After the implantation of implantable cardioverter-defibrillator, intermittent ventricular fibrillations still occurred during the 6-month follow-up. When the use of quinidine alone was insufficient to prevent electrical storms, lidocaine test and electrocardiographic characteristics can help guide drug selection. In pediatric SQTS, when high-dose quinidine fails to reduce the risk of sudden death, combination therapy with other antiarrhythmic drugs should be considered. Implantable cardioverter-defibrillator implantation remains the most effective method for preventing sudden death in children with SQTS.

PMID 42132729
Read full article →
PubMedJournal of cosmetic dermatology2026-05-14

Efficacy and Safety of Cryotherapy Combined With Intralesional Steroid for Keloid and Hypertrophic Scar: A Systematic Review and Meta-Analysis.

Feng Xiaowei X, Zou Xingwei X, Jiang Shali S, He Xin X et al.

Intralesional steroid injection is the first-line therapy for scars. Emerging evidence indicates that combining intralesional steroid injection with cryotherapy yields promising therapeutic outcomes for scar management. However, a consensus on the efficacy and safety of this combined regimen has not yet been reached. Consequently, the present meta-analysis aimed to assess the efficacy and safety of this combination compared with control groups. A full-scale literature retrieval was performed across a range of databases to identify eligible randomized controlled trials (RCTs) and prospective non-randomized studies that evaluated the efficacy and safety of cryotherapy plus intralesional steroid injection against control treatments for keloids or hypertrophic scars. Key outcome data, including the mean percentage change in scar improvement, the excellent clinical response rate (defined as ≥ 75% reduction in scar volume), and the incidence of adverse events, were extracted. Meta-analyses were performed using a fixed- or random-effects model based on the heterogeneity assessment results. Thirteen studies involving 1012 cases were included in this meta-analysis. The pooled results exhibited that cryotherapy combined with intralesional steroid injection yielded a significantly higher efficacy rate than various control interventions (including intralesional steroid monotherapy, cryotherapy alone, bleomycin/verapamil treatment, laser plus steroid, and surgical excision plus radiotherapy) (risk ratio [RR] = 1.19, 95% confidence interval (CI): 1.03-1.36; p = 0.01). However, no statistically significant differences were detected between the experimental and control groups in either the mean percentage change in scar improvement (standard mean difference (SMD) = 0.14, 95% CI: -0.39 to 0.68; p = 0.60) or the overall incidence of adverse events (RR = 1.35, 95% CI: 0.99-1.83; p = 0.06). Cryotherapy combined with intralesional steroid injection is a viable alternative to other first-line treatments for keloids and hypertrophic scars. Clinical recommendations should be made cautiously based on specific patient and scar conditions. Further well-designed, large-scale RCTs are required to validate the long-term efficacy and safety of this combined regimen.

PMID 42130027
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about verapamil